GRI Bio (GRI) Operating Income (2020 - 2026)
GRI Bio (GRI) posted quarterly Operating Income of -$2.0 million for Q1 2026, up 34.35% year-over-year from -$1.5 million in Q1 2025, and up 24.81% quarter-over-quarter from -$2.7 million in Q4 2025.
GRI Bio (GRI) Operating Income (2020 - 2026) Analysis & Trends
GRI Bio's Operating Income history runs 7 years deep, the most recent figure standing at -$2.0 million for Q1 2026.
- In Q1 2026, Operating Income rose 34.35% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$10.9 million (down 16.36% YoY), while the FY2025 annual figure was -$12.0 million, down 45.44% from the prior year.
- Operating Income for Q1 2026 stood at -$2.0 million, up from -$2.7 million in the prior quarter.
- The five-year high for Operating Income was -$186000.0 in Q3 2022, with the low at -$5.9 million in Q2 2023.
- The 5-year median for Operating Income is -$2.1 million (2024), against an average of -$2.3 million.
- The sharpest annual moves came in 2022 and 2023: Operating Income jumped 91.82% in 2022, then tumbled 3039.68% in 2023.
- GRI Bio's Operating Income stood at -$1.7 million in 2022, then decreased by 21.54% to -$2.0 million in 2023, then rose by 3.55% to -$2.0 million in 2024, then slumped by 36.34% to -$2.7 million in 2025, then rose by 24.81% to -$2.0 million in 2026.
- Business Quant data shows GRI's Operating Income at -$2.0 million in Q1 2026, -$2.7 million in Q4 2025, and -$3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 133.12 Mn |
| 10 | GRI Bio | 3.03 Mn | 3.03 Mn | - | -1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.00 Mn |
| Dec 31, 2025 | -2.66 Mn |
| Sep 30, 2025 | -3.37 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -3.05 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -2.26 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -2.03 Mn |
| Sep 30, 2023 | -2.44 Mn |
| Jun 30, 2023 | -5.93 Mn |
| Mar 31, 2023 | -988,000.00 |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -189,000.00 |
| Mar 31, 2022 | -2.63 Mn |
| Dec 31, 2021 | -3.09 Mn |
| Sep 30, 2021 | -1.25 Mn |
| Jun 30, 2021 | -2.31 Mn |